Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00331513 | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00470197 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00720850 | Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)(LENAMAINT) | terminated | Phase 2 | 10 | Technische Universität DresdenOTHER | 1 | Sep 27, 2013 | clinicaltrials |
| NCT01035502 | A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia | completed | Phase 2 | 51 | Clavis PharmaINDUSTRY | 4 | Sep 27, 2013 | clinicaltrials |
| NCT01147939 | Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)(CLAVELA) | completed | Phase 3 | 381 | Clavis PharmaINDUSTRY | 13 | Sep 27, 2013 | clinicaltrials |
| NCT01950611 | Proteasome Inhibition in Acute Promyelocytic Leukemia(PIAPL) | unknown | Phase 2 | 30 | Christian Medical College, Vellore, IndiaOTHER | 1 | Sep 25, 2013 | clinicaltrials |
| NCT00036712 | Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation | unknown | Phase 2 | 80 | Medical College of WisconsinOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT01159301 | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2013 | clinicaltrials |
| NCT00405743 | A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | completed | Phase 1 / Phase 2 | 153 | Clavis PharmaINDUSTRY | 6 | Sep 18, 2013 | clinicaltrials |
| NCT00882102 | Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) | completed | Phase 2 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2013 | clinicaltrials |
| NCT00684918 | Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML) | completed | Phase 2 | 18 | Gemin XINDUSTRY | 2 | Aug 26, 2013 | clinicaltrials |
| NCT00360672 | Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome | completed | Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00514722 | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies | terminated | N/A | 4 | University of California, San FranciscoOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00511537 | Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders | completed | — | 30 | University of California, San FranciscoOTHER | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00513318 | Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies | terminated | — | 15 | University of California, San FranciscoOTHER | 1 | Aug 2, 2013 | clinicaltrials |
| NCT01041040 | LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) | completed | Phase 4 | 200 | PETHEMA FoundationOTHER | 1 | Jul 31, 2013 | clinicaltrials |
| NCT00334074 | Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | completed | Phase 2 | 30 | Baylor Research InstituteOTHER | 1 | Jul 17, 2013 | clinicaltrials |
| NCT01901666 | Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission | unknown | Phase 4 | 20 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Jul 17, 2013 | clinicaltrials |
| NCT00697671 | Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies | completed | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00927498 | A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old | completed | Phase 3 | 280 | Acute Leukemia French AssociationOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT00478985 | Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia(STIM) | completed | N/A | 100 | University Hospital, BordeauxOTHER | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | completed | Phase 1 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 2, 2013 | clinicaltrials |
| NCT01887561 | Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial | unknown | Phase 2 | 100 | Kanto CML Study GroupOTHER | 1 | Jun 27, 2013 | clinicaltrials |
| NCT00003619 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | — | Drexel University College of MedicineOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00150878 | Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission | terminated | Phase 3 | 198 | University Hospital Carl Gustav CarusOTHER | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00460629 | Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation | completed | Phase 1 / Phase 2 | 20 | University Hospital Carl Gustav CarusOTHER | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00195000 | Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS | completed | Phase 2 | 43 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00014482 | Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation | completed | N/A | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2013 | clinicaltrials |
| NCT01608204 | Busulfan Pharmacokinetic Analysis and GST Pharmacogenetic Profile in Adults Undergoing Hematological Stem Cell Transplantation | completed | — | 63 | Rambam Health Care CampusOTHER | 0 | Jun 11, 2013 | clinicaltrials |
| NCT00003694 | Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00003934 | Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | completed | Phase 3 | 420 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00042900 | Pyroxamide in Treating Patients With Advanced Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00077467 | Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00079404 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00003190 | Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 3 | 640 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00006363 | Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | completed | Phase 3 | 720 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00017472 | Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00047190 | Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00049192 | Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00070551 | GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00093821 | Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors | completed | Phase 1 | 70 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00101231 | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | terminated | Phase 1 | 88 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | terminated | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01463410 | Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler | terminated | — | 264 | Skyline Diagnostics BVINDUSTRY | 4 | May 29, 2013 | clinicaltrials |
| NCT00358644 | Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML) | completed | Phase 2 | 55 | Eisai Inc.INDUSTRY | 1 | May 20, 2013 | clinicaltrials |
| NCT00357305 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00066417 | Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia | terminated | Phase 2 | 51 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | May 1, 2013 | clinicaltrials |
| NCT00393380 | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor | terminated | Phase 2 | 13 | The Emmes Company, LLCINDUSTRY | 1 | Apr 29, 2013 | clinicaltrials |
| NCT00899951 | Studying Fentanyl in Patients With Cancer | terminated | — | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 18, 2013 | clinicaltrials |
| NCT01503502 | A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | unknown | Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 10, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Sep 30, 2013source: clinicaltrials